EP3904355 - SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 18.10.2024 Database last updated on 19.10.2024 | |
Former | Grant of patent is intended Status updated on 10.06.2024 | ||
Former | Examination is in progress Status updated on 16.12.2022 | ||
Former | Request for examination was made Status updated on 01.10.2021 | ||
Former | The international publication has been made Status updated on 28.08.2020 | Most recent event Tooltip | 18.10.2024 | (Expected) grant | published on 20.11.2024 [2024/47] | Applicant(s) | For all designated states Shenzhen TargetRx, Inc. Room 301 Unit 1 Building A Kexing Science Park No.15 of Keyuan Road Nanshan District Shenzhen, Guangdong 518057 / CN | [2021/44] | Inventor(s) | 01 /
WANG, Yihan Room 301, Building A1 Kexing Science Park No.15 of Keyuan Road Nanshan District Shenzhen, Guangdong 518057 / CN | 02 /
XING, Qingfeng Room 301, Building A1 Kexing Science Park No.15 of Keyuan Road Nanshan District Shenzhen, Guangdong 518057 / CN | 03 /
AI, Yixin Room 301, Building A1 Kexing Science Park No.15 of Keyuan Road Nanshan District Shenzhen, Guangdong 518057 / CN | [2024/47] |
Former [2021/44] | 01 /
WANG, Yihan Shenzhen, Guangdong 518057 / CN | ||
02 /
XING, Qingfeng Shenzhen, Guangdong 518057 / CN | |||
03 /
AI, Yixin Shenzhen, Guangdong 518057 / CN | Representative(s) | Novitas Patent AB P.O. Box 55557 102 04 Stockholm / SE | [2021/44] | Application number, filing date | 20759406.0 | 13.02.2020 | [2021/44] | WO2020CN74983 | Priority number, date | CN201910127767 | 18.02.2019 Original published format: CN201910127767 | [2021/44] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020168963 | Date: | 27.08.2020 | Language: | ZH | [2020/35] | Type: | A1 Application with search report | No.: | EP3904355 | Date: | 03.11.2021 | Language: | EN | [2021/44] | Type: | B1 Patent specification | No.: | EP3904355 | Date: | 20.11.2024 | Language: | EN | [2024/47] | Search report(s) | International search report - published on: | CN | 27.08.2020 | (Supplementary) European search report - dispatched on: | EP | 11.02.2022 | Classification | IPC: | C07D487/04, C07D471/04, A61P35/00, A61K31/33 | [2022/11] | CPC: |
C07D487/04 (EP,CN,US);
A61P35/00 (EP,CN);
A61P35/02 (EP,CN);
C07D471/04 (EP,CN,US)
|
Former IPC [2021/44] | C07D471/04, C07D401/04, C07D403/14, C07D403/04, C07D405/14, C07D413/14, C07D413/04, A61P35/00, A61K31/33 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/44] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | SUBSTITUIERTE KONDENSIERTE AROMATISCHE RINGDERIVATE, ZUSAMMENSETZUNG UND DEREN VERWENDUNG | [2021/44] | English: | SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF | [2021/44] | French: | DÉRIVÉ DE CYCLE AROMATIQUE FUSIONNÉ SUBSTITUÉ, COMPOSITION ET UTILISATION DE CELUI-CI | [2021/44] | Entry into regional phase | 29.07.2021 | Translation filed | 29.07.2021 | National basic fee paid | 29.07.2021 | Search fee paid | 29.07.2021 | Designation fee(s) paid | 29.07.2021 | Examination fee paid | Examination procedure | 29.07.2021 | Examination requested [2021/44] | 31.08.2022 | Amendment by applicant (claims and/or description) | 15.12.2022 | Despatch of a communication from the examining division (Time limit: M04) | 14.04.2023 | Reply to a communication from the examining division | 05.09.2023 | Despatch of a communication from the examining division (Time limit: M04) | 04.01.2024 | Reply to a communication from the examining division | 11.06.2024 | Communication of intention to grant the patent | 09.10.2024 | Fee for grant paid | 09.10.2024 | Fee for publishing/printing paid | 09.10.2024 | Receipt of the translation of the claim(s) | Fees paid | Renewal fee | 27.01.2022 | Renewal fee patent year 03 | 26.01.2023 | Renewal fee patent year 04 | 30.01.2024 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]WO2006091671 (LILLY CO ELI [US], et al) [X] 1-7,14,15 * examples 167,172,173,204,205,219,225,275,303,317; claims 1,16 *; | [Y]WO2006108640 (NOVARTIS AG [CH], et al) [Y] 1-15 * claims 1,16 *; | [Y]WO2015187818 (UNIV ARIZONA STATE [US]) [Y] 1-15 * claims 1,38,40, 44 *; | [E]WO2021057877 (SHENZHEN TARGETRX INC [CN]) [E] 1-15* claims 1,13 *; | [X] - CHEN YUEFENG ET AL, "Developing and applying a gene functional association network for anti-angiogenic kinase inhibitor activity assessment in an angiogenesis co-culture model", BMC GENOMICS, BIOMED CENTRAL LTD, LONDON, UK, (20080602), vol. 9, no. 1, ISSN 1471-2164, page 264, XP021033000 [X] 1-6,14,15 * figure 7B * | International search | [X]EP1382603 (EISAI CO LTD [JP]) [X] 1, 2, 5-9, 17-20, 25 * description, embodiments 477-488, 499, 505, 507-513, 515-521, 639-641, 645, 649-660, 671, 678, 680-696, 702-706, 721, 728, 754, 755, 759, 760, 871-875, 1088 and 1092, and claims 15-31 *; | [X]WO2004078756 (EISAI LONDON RES LAB LTD [GB], et al) [X] 1, 5-9 * description, page 30 *; | [X]WO2007112093 (SYNTA PHARMACEUTICALS CORP [US], et al) [X] 1, 2, 5, 8, 9 * description, table 1 *; | [X]CN101128461 (LILLY CO ELI [US]) [X] 1, 2, 4-25 * claims 18-20, and description, embodiment *; | [A]CN102266341 (GUANGZHOU NO. 12 PEOPLE'S HOSPITAL) [A] 1-25 * entire document *; | [A]CN104513252 (GUANGDONG HEC PHARMACEUTICAL) [A] 1-25* entire document *; | [X]WO2018035061 (NEUPHARMA INC [US]) [X] 1-3, 7, 8 * description, paragraph [0451] *; | [X]CN108948002 (UNIV XIAMEN) [X] 1-3, 5, 7, 8, 17-20, 25 * claims 11, 13 and 14 *; | [X] - CHEN, Y. F. et al., "Developing and Applying a Gene Functional Association Network for Anti-angiogenic Kinase Inhibitor Activity Assessment in an Angiogenesis Co-culture Model", BMC Genomic, (20080602), vol. 9, doi:20200415173418X, XP021033000 [X] 1, 2, 4-8 * figure 7 * | [X] - Anonymous, "- Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[2-fluoro-4-[7-[4-(1- piperazinylcarbonyl)phenyl]imidazo[1,2-a]pyridin-3-yl]phenyl]- (CA INDEX NAME)", REGISTRY, (20060922), Database accession no. 908329-69-1, URL: STN, XP055834256 [X] 1, 2, 4-10 | [PX] - Anonymous, "Benzamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(1,2,4-triazolo[4,3- a]pyrimidin-3-yl)- (CA INDEX NAME)", REGISTRY, (20190516), Database accession no. 2309151-24-2, URL: STN, XP055834271 [PX] 1, 2, 7, 8 | by applicant | US5376645 | - BERGE et al., "describe pharmaceutically acceptable salts in detail", J. Pharmaceutical Sciences, (19770000), vol. 66, pages 1 - 19 | - T. HIGUCHIV. STELLA, "Prodrugs as Novel Delivery Systems", A.C.S. Symposium Series, vol. 14 | - "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", D. FLEISHERS. RAMONH. BARBRA, Advanced Drug Delivery Reviews, (19960000), vol. 19, pages 115 - 130 |